Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results
Kim Papp, Mark Lebwohl, L. Puig, Mamitaro Ohtsuki, Stefan Beissert, Melinda Gooderham, Ahmad Z. Amin, Tianshuang Wu, Simone Rubant, Brenton Bialik, Doug Ashley, Ahmed M. Soliman, Michael M. Chen, Andrew Blauvelt
Topics & Concepts
MedicinePsoriasis Area and Severity IndexPsoriasisDiscontinuationAdverse effectInternal medicineDermatology Life Quality IndexRandomized controlled trialSeverity of illnessDermatologyPsoriasis: Treatment and PathogenesisSpondyloarthritis Studies and TreatmentsBiological Research and Disease Studies